We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precis... Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Show more
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc...
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.28 | -5.1376146789 | 5.45 | 5.52 | 5.07 | 242464 | 5.2657143 | CS |
4 | -1.37 | -20.9480122324 | 6.54 | 6.68 | 4.94 | 405671 | 5.68213979 | CS |
12 | 0.59 | 12.8820960699 | 4.58 | 6.79 | 4.46 | 376320 | 5.60912997 | CS |
26 | 1.81 | 53.869047619 | 3.36 | 6.79 | 2.5 | 290275 | 4.95532981 | CS |
52 | 3.17 | 158.5 | 2 | 6.79 | 1.96 | 277412 | 4.44962951 | CS |
156 | -5.4 | -51.0879848628 | 10.57 | 11.1 | 1.86 | 145663 | 5.0181181 | CS |
260 | -15.83 | -75.380952381 | 21 | 22 | 1.86 | 137560 | 6.62251183 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions